“…However, it appears that the former strategy is very time consuming and quite costly as extensive quality control (such as entire genome sequencing) needs to be performed on each of the individual patient-specific iPSC lines owing to the elevated risk of generating random mutations, which could possibly lead to tumor formation during the iPSC generation protocol (Kamao et al, 2014). Homozygous HLA matched iPSC quality tested, banked and clinically safe cell lines from healthy donors (like those found at the CiRA Center, Kyoto University, Japan) also hold much promise for stem cell based therapies (Sugita et al, 2016; Takahashi and Yamanaka, 2016), but the current limited number of lines available makes this an option for only a small percent of the world's population (Karagiannis and Eto, 2016; Sakurai et al, 2016). In a recent interview, Shinya Yamanaka, who developed the strategy for iPSC generation (Takahashi and Yamanaka, 2006, 2016) suggested that iPSCs would likely only be useful for treating approximately nine human diseases (spinal cord injury, joint disorders, Parkinson's, specific blood disorders, heart and liver failure, retinal and corneal diseases, and diabetes) over the next decade or so, and IVD-related diseases were not among them (Ravven, 2017).…”